>R&D >R&D in Takeda

R&D in Takeda

Takeda determines its R&D strategy based on the latest medical needs. By concentrating investment of management resources in the core therapeutic areas of Cardiovascular & Metabolic, Oncology, Central Nervous System, Immunology & Respiratory, General Medicine and Vaccine, Takeda strives to achieve leading innovation in medicine.


  •  

R&D News

Latest Publications of Takeda Research Laboratories

R&D At a Glance

Main R&D Facilities

Takeda Pharmaceuticals International, Inc. (Deerfield, U.S.)

Multilab Indústria e Comércio de Produtos Farmacêuticos Ltda. ( São Jerônimo, Brazil)

Millennium Pharmaceuticals, Inc. (Cambridge, MA, U.S.)

Takeda California, Inc. (San Diego, CA, U.S.)

Envoy Therapeutics, Inc. (San Diego, CA, U.S.)

Takeda Vaccines (Montana), Inc. (Bozeman, MT, U.S.)

Takeda Global Research & Development Center, Inc. (Deerfield, IL. U.S.)

Takeda Ventures, Inc. (Palo Alto, CA, U.S.)

Takeda GmbH (Konstanz, Germany)

Takeda Pharma A/S (Roskilde, Denmark)

Takeda Cambridge Limited (Cambridge, U.K.)

Takeda Global Research & Development Centre (Europe), Ltd. (London, U.K.)
Takeda (China) Holdings Co., Ltd. (Shanghai, China)
Guangdong Techpool Bio-Pharma Co., Ltd. (Guangzhou, China) 
Takeda Singapore Pte Limited (Singapore)

Takeda Global Research & Development Center (Asia) Pte. Ltd. (Singapore)

Shonan Research Center (Fujisawa, Japan)
Japan Development Center (Osaka, Japan)
Takeda Bio Development Center Limited (Tokyo, Japan)
CMC Center (Osaka, Japan)

R&D Investment ¥324.3 billion (FY2012)
Royalty Income ¥45.2 billion (FY2012)
Core Therapeutic Areas Cardiovascular & Metabolic
Oncology
Central Nervous System
Immunology & Respiratory
General Medicine
Vaccine
R&D Pipeline Takeda discloses ethical drugs under development that have reached phase I or higher status